Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
The management of AL amyloidosis and immunoglobulin disease during the COVID-19 pandemic should be individualized based on several patient-specific aspects.
Researchers studied survival in reduced-intensity conditioning HSCT vs non-HSCT approaches for older, transplantation-eligible patients with advanced MDS.
Study results suggest that for patients with anemia, preoperative iron therapy should not be recommended in major election surgery.
While several studies have investigated SARS-CoV-2 contamination in health care settings, patterns in oncology clinics with fewer COVID-19 cases is unclear.
Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.
Among patients with cancer, tumor subtypes may influence varying susceptibility to SARS-CoV-2 and COVID-19 disease phenotypes.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Even after treatment with hypomethylating agents, older patients with AML still lack positive prognoses but azacitidine with venetoclax shows promise.
